X @Bloomberg
Bloomberg·2026-04-30 01:48
Avalyn, a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US IPO that priced at the top of its marketed range https://t.co/UjcTvRb49k ...
Avalyn, a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US IPO that priced at the top of its marketed range https://t.co/UjcTvRb49k ...